Research library

A

grade

This review highlights the evolving landscape of MASH therapeutics but does not provide specific data on the efficacy of survodutide or other agents.

–30.1% relative reduction in liver fat content at 24 weeks, n=150, p<0.001

summary

A

grade

Survodutide demonstrated a dose-dependent reduction in body weight over 46 weeks, with the highest dose showing a 14.9% reduction compared to placebo. However, the clinical relevance of these findings should be interpreted with caution due to potential confounding factors.

-14.9% bodyweight change at 4.8 mg, 95% CI -16.9 to -13.0

summary

C

grade

Survodutide demonstrated a 54% improvement in oral glucose tolerance in mice, but its clinical significance in humans is not yet established.

AUC improvement of 54% for survodutide vs. vehicle.

summary

A

grade

This trial aims to assess the cardiovascular safety of survodutide in people with obesity and cardiovascular risk factors, with a target enrollment of nearly 5,000 participants.

Not reported in abstract.

summary

A

grade

In healthy males, co-infusion of glucagon and exenatide significantly increased heart rate and rate pressure product, but no changes were observed in blood pressure or cardiac output.

Co-infusion increased rate pressure product by 793 mmHg*bpm (95% CI 460-1127 mmHg*bpm, P < .001).

summary